JP7496838B2 - 置換１－オキソ－イソインドリン－５－カルボキサミド化合物、その組成物、およびそれによる治療方法 - Google Patents

置換１－オキソ－イソインドリン－５－カルボキサミド化合物、その組成物、およびそれによる治療方法 Download PDF

Info

Publication number
JP7496838B2
JP7496838B2 JP2021570866A JP2021570866A JP7496838B2 JP 7496838 B2 JP7496838 B2 JP 7496838B2 JP 2021570866 A JP2021570866 A JP 2021570866A JP 2021570866 A JP2021570866 A JP 2021570866A JP 7496838 B2 JP7496838 B2 JP 7496838B2
Authority
JP
Japan
Prior art keywords
carboxamide
dioxopiperidin
oxo
isoindoline
trifluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021570866A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022534979A (ja
JPWO2020243379A5 (https=
JP2022534979A5 (https=
Inventor
バクリ，フランズ
ノースコート，キャサリン
ディ コレア，マシュー
ハンセン，ジョシュア
エイ ルブラン，ローリー
ルゥ，チン－チュン
ルー，ガン
エイ ナギー，マーク
ペン，ソフィー
ペリン－ニンコビック，ソフィー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2022534979A publication Critical patent/JP2022534979A/ja
Publication of JPWO2020243379A5 publication Critical patent/JPWO2020243379A5/ja
Publication of JP2022534979A5 publication Critical patent/JP2022534979A5/ja
Priority to JP2024086242A priority Critical patent/JP2024123001A/ja
Application granted granted Critical
Publication of JP7496838B2 publication Critical patent/JP7496838B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021570866A 2019-05-31 2020-05-29 置換１－オキソ－イソインドリン－５－カルボキサミド化合物、その組成物、およびそれによる治療方法 Active JP7496838B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024086242A JP2024123001A (ja) 2019-05-31 2024-05-28 置換１－オキソ－イソインドリン－５－カルボキサミド化合物、その組成物、およびそれによる治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962855619P 2019-05-31 2019-05-31
US62/855,619 2019-05-31
PCT/US2020/035043 WO2020243379A1 (en) 2019-05-31 2020-05-29 Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024086242A Division JP2024123001A (ja) 2019-05-31 2024-05-28 置換１－オキソ－イソインドリン－５－カルボキサミド化合物、その組成物、およびそれによる治療方法

Publications (4)

Publication Number Publication Date
JP2022534979A JP2022534979A (ja) 2022-08-04
JPWO2020243379A5 JPWO2020243379A5 (https=) 2023-05-30
JP2022534979A5 JP2022534979A5 (https=) 2023-05-30
JP7496838B2 true JP7496838B2 (ja) 2024-06-07

Family

ID=73551319

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021570866A Active JP7496838B2 (ja) 2019-05-31 2020-05-29 置換１－オキソ－イソインドリン－５－カルボキサミド化合物、その組成物、およびそれによる治療方法
JP2024086242A Pending JP2024123001A (ja) 2019-05-31 2024-05-28 置換１－オキソ－イソインドリン－５－カルボキサミド化合物、その組成物、およびそれによる治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024086242A Pending JP2024123001A (ja) 2019-05-31 2024-05-28 置換１－オキソ－イソインドリン－５－カルボキサミド化合物、その組成物、およびそれによる治療方法

Country Status (19)

Country Link
US (2) US11306101B2 (https=)
EP (1) EP3976595A4 (https=)
JP (2) JP7496838B2 (https=)
KR (2) KR20250078628A (https=)
CN (4) CN119930578A (https=)
AR (1) AR119057A1 (https=)
AU (1) AU2020282748A1 (https=)
BR (1) BR112021022758A2 (https=)
CA (1) CA3136753A1 (https=)
CL (1) CL2021003134A1 (https=)
CO (1) CO2021015624A2 (https=)
IL (1) IL288278B2 (https=)
MX (1) MX2021014350A (https=)
MY (1) MY208545A (https=)
PE (1) PE20220569A1 (https=)
SG (1) SG11202112872YA (https=)
TW (2) TW202523657A (https=)
WO (1) WO2020243379A1 (https=)
ZA (1) ZA202109003B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020243379A1 (en) 2019-05-31 2020-12-03 Celgene Corporation Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
IL302038A (en) * 2020-10-14 2023-06-01 C4 Therapeutics Inc Tricyclic ligands for degradation of ikzf2 or ikzf4
CN112679421A (zh) * 2021-01-04 2021-04-20 都创(上海)医药科技股份有限公司 一种(r)-3-氯吡啶基-2-三氟乙胺盐酸盐的合成方法
JP2024504932A (ja) 2021-01-13 2024-02-02 モンテ ローザ セラピューティクス， インコーポレイテッド イソインドリノン化合物
CN118019534A (zh) * 2021-05-06 2024-05-10 细胞基因公司 使用n-((r)-1-(3-氯吡啶-2-基)-2,2,2-三氟乙基)-2-((s)-2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-甲酰胺的治疗方法
US20240294500A1 (en) * 2021-06-08 2024-09-05 Hangzhou Glubio Pharmaceutical Co., Ltd. Isoindolinone compounds, and uses thereof
CN115504963A (zh) * 2021-06-22 2022-12-23 苏州开拓药业股份有限公司 一种c-Myc蛋白降解剂
EP4452415B1 (en) 2021-12-22 2026-02-25 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CA3253296A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Zinc Finger Degradation Agents of the Ikaros Family and Their Uses
WO2023244815A1 (en) * 2022-06-16 2023-12-21 Monte Rosa Therapeutics, Inc. Molecular glue degraders and methods of using the same
WO2023244818A1 (en) * 2022-06-16 2023-12-21 Monte Rosa Therapeutics, Inc. Molecular glue degraders and methods of using the same
US20260055077A1 (en) * 2022-08-01 2026-02-26 Suzhou Kintor Pharmaceuticals, Inc. Protein degradation agent
WO2024120441A1 (zh) * 2022-12-07 2024-06-13 杭州格博生物医药有限公司 氧异吲哚-5-甲酰胺类化合物或其盐、溶剂合物的结晶形式或无定形形式
WO2024120438A1 (zh) * 2022-12-07 2024-06-13 杭州格博生物医药有限公司 一种固体分散体、其制备方法和应用
PL249026B1 (pl) * 2022-12-09 2026-02-23 Univ Mikolaja Kopernika W Toruniu Pochodna azetydyno-2,4-dionu, sposób jej otrzymywania i zastosowanie

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006089495A (ja) 2000-12-27 2006-04-06 Celgene Corp イソインドール−イミド化合物、組成物、およびそれらの使用
JP2009506117A (ja) 2005-08-31 2009-02-12 セルジーン・コーポレーション イソインドール−イミド化合物及びそれを含有する組成物及びそれの使用法
JP2010502627A (ja) 2006-08-30 2010-01-28 セルジーン・コーポレーション ５−置換イソインドリン化合物
JP2011522803A (ja) 2008-05-30 2011-08-04 セルジーン コーポレイション ５−置換イソインドリン化合物
WO2017024319A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
JP2017525757A (ja) 2014-07-11 2017-09-07 セルジーン コーポレイション 抗増殖性化合物及びその使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
ZA200901078B (en) * 2006-08-30 2010-06-30 Celgene Corp 5-substituted isoindoline compounds
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017024317A2 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2020243379A1 (en) 2019-05-31 2020-12-03 Celgene Corporation Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006089495A (ja) 2000-12-27 2006-04-06 Celgene Corp イソインドール−イミド化合物、組成物、およびそれらの使用
JP2009506117A (ja) 2005-08-31 2009-02-12 セルジーン・コーポレーション イソインドール−イミド化合物及びそれを含有する組成物及びそれの使用法
JP2010502627A (ja) 2006-08-30 2010-01-28 セルジーン・コーポレーション ５−置換イソインドリン化合物
JP2011522803A (ja) 2008-05-30 2011-08-04 セルジーン コーポレイション ５−置換イソインドリン化合物
JP2017525757A (ja) 2014-07-11 2017-09-07 セルジーン コーポレイション 抗増殖性化合物及びその使用方法
WO2017024319A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry Letters，2004年，14(2)，421-425
Journal of Medicinal Chemistry，2018年，61(2)，492-503

Also Published As

Publication number Publication date
JP2024123001A (ja) 2024-09-10
JP2022534979A (ja) 2022-08-04
CA3136753A1 (en) 2020-12-03
IL288278B1 (en) 2025-05-01
CO2021015624A2 (es) 2022-02-28
MY208545A (en) 2025-05-14
AU2020282748A1 (en) 2021-12-09
CN119930578A (zh) 2025-05-06
TWI851729B (zh) 2024-08-11
KR102913106B1 (ko) 2026-01-19
US20220213115A1 (en) 2022-07-07
SG11202112872YA (en) 2021-12-30
EP3976595A4 (en) 2023-01-04
TW202523657A (zh) 2025-06-16
CN114957212B (zh) 2024-05-24
MX2021014350A (es) 2022-02-21
CN114269729A (zh) 2022-04-01
BR112021022758A2 (pt) 2022-03-22
CN114269729B (zh) 2025-01-17
IL288278A (en) 2022-01-01
CN114957212A (zh) 2022-08-30
CL2021003134A1 (es) 2022-07-01
US20200377512A1 (en) 2020-12-03
ZA202109003B (en) 2025-01-29
KR20220016167A (ko) 2022-02-08
PE20220569A1 (es) 2022-04-20
TW202110819A (zh) 2021-03-16
US11306101B2 (en) 2022-04-19
CN118724867A (zh) 2024-10-01
IL288278B2 (en) 2025-09-01
KR20250078628A (ko) 2025-06-02
EP3976595A1 (en) 2022-04-06
US12486281B2 (en) 2025-12-02
WO2020243379A1 (en) 2020-12-03
AR119057A1 (es) 2021-11-17

Similar Documents

Publication Publication Date Title
JP7496838B2 (ja) 置換１－オキソ－イソインドリン－５－カルボキサミド化合物、その組成物、およびそれによる治療方法
US11945804B2 (en) Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith
TW201629063A (zh) 經取代胺基嘌呤化合物、其組合物及用其之治療方法
US20260098028A1 (en) Compounds and Their Use for Treatment of Hemoglobinopathies
JP2026505349A (ja) 改変されたタンパク質の選択的分解のための化合物および組成物
EA050422B1 (ru) Замещенные 1-оксоизоиндолин-5-карбоксамидные соединения, содержащие их композиции и способы лечения с их помощью
EA046753B1 (ru) Замещенные 1-оксоизоиндолин-5-карбоксамидные соединения, содержащие их композиции и способы лечения с их помощью
HK40102392A (en) Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma
BR112022019057B1 (pt) Aminotiazóis substituídos como inibidores de dgkzeta para ativação imune, seus usos, composição e combinação farmacêuticas, e kit
HK40049471B (en) Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma
HK40049471A (en) Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230519

TRDD Decision of grant or rejection written
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240425

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240528

R150 Certificate of patent or registration of utility model

Ref document number: 7496838

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150